Krasney Karen

Avg. Two Year Performance

(25%) Avg. Purchase Return
(12%) Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return32%48%63%35%(25%)
Purchase Success Rate1 of 11 of 11 of 11 of 10 of 1
Average Sale Return----------
Sale Success Rate----------

Nile Therapeutics, Inc

Drugs » Biotechnology

EVP, General Counsel:

Holdings: 20.05K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--